THERAPEUTIC DRUG MONITORING OF INFLIXIMAB AND ADALIMUMAB FOR DETECTION OF PATIENTS AT RISK OF LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE.

Jaime González-López  ¹     Manuel Barreiro de Acosta  ²     José M Giráldez-Montero  ³     Rocio Ferreiro Iglesias     María Jesús Lamas-Díaz     Juan Enrique Dominguez-Munoz    
¹ University Hospital of Santiago de Compostela, Pharmacy, Santiago de Compostela, Spain
² University Hospital of Santiago de Compostela. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, Gastroenterology, Santiago de Compostela, Spain
³ University Hospital of Santiago de Compostela, Pharmacy, Santiag

Conference
UEG Week 2016

Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)